SCHEMBL769270

SCHEMBL769270

C#Cc1cccc(N)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3898971 0.88 NOS3 (0.36)
SCHEMBL982334 0.82 CYP1A1 (0.37)
SCHEMBL913399 0.76
SCHEMBL30779745 0.76
SCHEMBL17039219 0.73 NOS3 (0.46)
SCHEMBL19062737 0.73 GRM5 (0.39)
SCHEMBL64599 0.73
SCHEMBL16288839 0.71
SCHEMBL3510212 0.71
SCHEMBL18737312 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973886-B1 PROKINETICIN 1 RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2013-02-27 EP claimed
US-11396508-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2022-07-26 US disclosed
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
US-20210094948-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-04-01 US disclosed
EP-3738591-A2 NOVEL ANTIBACTERIAL AGENTS MERCK SHARP & DOHME CORP. (US) 2020-11-18 EP disclosed
EP-3738591-A2 NOVEL ANTIBACTERIAL AGENTS MERCK SHARP & DOHME CORP. (US) 2020-11-18 EP disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
US-10647713-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2020-05-12 US disclosed
CN-110300590-A TYK2 inhibitor and application thereof 林伯士拉克许米公司 2019-10-01 CN disclosed
EP-3528816-A1 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2019-08-28 EP disclosed
US-20090209593-A1 NOVEL ANTIBACTERIAL AGENTS TETARD, INC. 2009-08-20 US disclosed
US-20090209593-A1 NOVEL ANTIBACTERIAL AGENTS TETARD, INC. 2009-08-20 US disclosed
US-20090209593-A1 NOVEL ANTIBACTERIAL AGENTS TETARD, INC. 2009-08-20 US disclosed
EP-1654251-A4 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2009-03-11 EP disclosed
US-20060205740-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2006-09-14 US disclosed
US-20060100164-A1 11-N-[4-(4-Pyridin-3-yl-imidazol-1-yl)-butyl]-6-O-methyl-5-O-(3-dimethylamino-2-hydroxy-propoxy)-3-oxo-erythronolide A, 11,12-carbamate; functionalized macrolides; antiviral, antiprotozoal, anticancer and antigastrointestinal TETARD, INC. 2006-05-11 US disclosed
EP-1654251-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-05-10 EP disclosed
EP-1638549-A2 NOVEL ANTIBACTERIAL AGENTS Optimer Pharmaceuticals, Inc. (US) 2006-03-29 EP disclosed
WO-2005016914-A1 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-02-24 WO disclosed
WO-2004080391-A2 NOVEL ANTIBACTERIAL AGENTS OPTIMER PHARMACEUTICALS, INC. (US) 2004-09-23 WO disclosed